Svatek RS - Search Results

1

Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.

Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, Shariat SF. Sonpavde G, et al. Among authors: svatek rs. J Urol. 2011 Feb;185(2):456-61. doi: 10.1016/j.juro.2010.09.110. Epub 2010 Dec 17. J Urol. 2011. PMID: 21167527

2

Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?

Svatek RS, Lee D, Lotan Y. Svatek RS, et al. Urology. 2005 Jul;66(1):65-8. doi: 10.1016/j.urology.2005.02.003. Urology. 2005. PMID: 15992876

3

Application of novel hemostatic agent during laparoscopic partial nephrectomy.

Margulis V, Matsumoto ED, Svatek R, Kabbani W, Cadeddu JA, Lotan Y. Margulis V, et al. J Urol. 2005 Aug;174(2):761-4. doi: 10.1097/01.ju.0000164727.53999.fe. J Urol. 2005. PMID: 16006972

4

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Svatek R, et al. Eur Urol. 2006 Apr;49(4):666-74. doi: 10.1016/j.eururo.2005.11.032. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16423446

5

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

6

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

7

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Among authors: svatek rs. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

8

The cost of prostate cancer chemoprevention: a decision analysis model.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896037

9

The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma.

Svatek RS, Lotan Y, Herman MP, Duchene DA, Sagalowsky AI, Cadeddu JA. Svatek RS, et al. J Urol. 2006 Oct;176(4 Pt 1):1321-5; discussion 125. doi: 10.1016/j.juro.2006.06.008. J Urol. 2006. PMID: 16952621

10

Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.

Abdel-Aziz KF, Anderson JK, Svatek R, Margulis V, Sagalowsky AI, Cadeddu JA. Abdel-Aziz KF, et al. J Endourol. 2006 Sep;20(9):627-31. doi: 10.1089/end.2006.20.627. J Endourol. 2006. PMID: 16999613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters